ArticleMetabolic brain disease2026
Castanopsis echinocarpa extract attenuates diabetes-associated peripheral-to-central auditory electrophysiological dysfunction in streptozotocin-induced diabetic mice.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Diabetes-associated auditory dysfunction may extend beyond cochlear threshold elevation and involve broader metabolic and auditory neural abnormalities. This study investigated whether Castanopsis echinocarpa extract (CAE) attenuates peripheral-to-central auditory electrophysiological dysfunction in streptozotocin (STZ)-induced diabetic mice and modulates related auditory and pancreatic stress responses. HEI-OC1 auditory cells were exposed to neomycin or inflammatory cytokines, and Tnf, Il1b, Trpv1, and Gjb2 mRNA expression was analyzed. Post-exposure otic hair cell recovery was assessed in neomycin-treated zebrafish larvae. MIN6 pancreatic β-cells and isolated pancreatic islet cells were used to evaluate oxidative and cytokine-induced β-cell injury. In vivo effects were examined in STZ-induced diabetic mice by measuring fasting blood glucose and auditory brainstem, middle-latency, and late-latency responses. CAE reduced neomycin- and cytokine-induced auditory cell injury, suppressed Tnf, Il1b, and Trpv1 upregulation, and partially restored Gjb2 expression in HEI-OC1 cells. CAE also supported otic hair cell recovery after neomycin injury. In pancreatic models, CAE attenuated H₂O₂- and cytokine-induced β-cell injury and reduced inflammatory gene responses. In STZ-induced diabetic mice, CAE lowered fasting blood glucose and improved ABR threshold shifts as well as AMLR and ALLR latency and amplitude abnormalities. These findings demonstrate concurrent improvements in metabolic and auditory outcomes following CAE treatment in STZ-induced diabetic mice and support further investigation of CAE as a multi-target candidate for diabetes-associated auditory dysfunction.
Indexed as
Identifiers
42804001What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.